Table 2 Haemodynamic variables during the study protocol
High dose of NE | Low dose of NE | |||
|---|---|---|---|---|
Baseline | PLR | Baseline | PLR | |
SAP (mmHg) | 141 [25] | 146 [25] | 120 [17] b | 127 [23]c |
DAP (mmHg) | 60 [9] | 63 [11]a | 54 [7]b | 58 [8]c |
MAP (mmHg) | 88 [12] | 94 [13] | 76 [8]b | 80 [10]c |
Heart rate (beats/min) | 93 [16] | 96 [15] | 92 [14] | 96 [14] |
CVP (mmHg) | 13.0 [5.0] | 15.8 [5.8]a | 12.4 [5.2] | 14.3 [5.9]c |
Pms (mmHg) | 30.7 [10.3] | 35.6 [11.2]a | 27.7 [9.7]b | 30.5 [10.4]c |
Pms-PVC (mmHg) | 17.6 [9.8] | 19.7 [11.2] | 15.3 [9.7]b | 16.2 [9.8] |
Indexed venous resistance (mmHg.min.m2/L) | 5.4 [2.7] | 5.5 [2.9] | 4.9 [2.7] | 4.7 [2.3] |
Indexed arterial resistance (mmHg.min.m2/L) | 17.7 [8.3] | 16.4 [10.0]a | 15.6 [6.1]b | 14.4 [6.1] |
Cardiac index (L/min/m2) | 3.24 [0.9] | 3.57 [0.9]a | 3.08 [0.7]b | 3.43 [0.8]c |
Dose of NE (μg/kg/min) | 0.32 [0.2–0.6] | 0.32 [0.2–0.6] | 0.26 [0.1–0.5]b | 0.26 [0.1–0.5] |
Cardiac function index (/min) | 4.8 [1.3] | 4.9 [1.5] | ||